Small-molecule inhibitors of protein-protein interactions: Progressing toward the reality

Chemistry and Biology

Volumn 21, Issue 9, 2014, Pages 1102-1114

  Arkin, Michelle R ^a   Tang, Yinyan ^a   Wells, James A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 (4 CHLOROPHENYL) N ETHYL 8 METHOXY 1 METHYL 4H [1,2,4]TRIAZOLO[4,3 A][1,4]BENZODIAZEPINE 4 ACETAMIDE; ACETIC ACID; APABETALONE; BIRINAPANT; EFALIZUMAB; GROWTH FACTOR; IDASANUTLIN; INHIBITOR OF APOPTOSIS PROTEIN 1; INHIBITOR OF APOPTOSIS PROTEIN 2; INTEGRASE; INTERLEUKIN 17; INTERLEUKIN 2; LIFITEGRAST; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; NAVITOCLAX; PROTEIN BAD; PROTEIN BAK; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN INHIBITOR; PROTEIN LENS ENDOTHELIAL GROWTH FACTOR; PROTEIN MCL 1; PROTEIN MDM2; PROTEIN PROTEIN INTERACTION INHIBITOR; UNCLASSIFIED DRUG; VENETOCLAX; [2 (4 TERT BUTYL 2 ETHOXYPHENYL) 4,5 BIS(4 CHLOROPHENYL) 4,5 DIHYDRO 4,5 DIMETHYL 1H IMIDAZOL 1 YL][4 [3 (METHYLSULFONYL)PROPYL] 1 PIPERAZINYL]METHANONE; APOPTOSIS REGULATORY PROTEIN; MOLECULAR LIBRARY; PEPTIDE; PROTEIN;

ALLOSTERISM; AMINO ACID SEQUENCE; APOPTOSIS; BINDING SITE; CELL FATE; CHROMOSOME; CRYSTAL STRUCTURE; ENZYME ACTIVE SITE; HUMAN; NONHUMAN; PROTEIN PROTEIN INTERACTION; PROTEIN SECONDARY STRUCTURE; PROTEIN TERTIARY STRUCTURE; REVIEW; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG EFFECTS; METABOLISM; MOLECULAR LIBRARY; PHARMACOLOGY; PROTEIN DOMAIN;

ALLOSTERIC REGULATION; APOPTOSIS REGULATORY PROTEINS; BINDING SITES; HIV INTEGRASE; HUMANS; PEPTIDES; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN INTERACTION MAPS; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY; PROTEINS; SMALL MOLECULE LIBRARIES;

EID: 84909587217     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chembiol.2014.09.001     Document Type: Review

References (116)

1. Arkin, M.R., and Wells, J.A. (2004). Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nat. Rev. Drug Discov. 3, 301-317.
2. Azzarito, V., Long, K., Murphy, N.S., and Wilson, A.J. (2013). Inhibition of α-helix-mediated protein-protein interactions using designed molecules. Nat. Chem. 5, 161-173.
3. Bai, L., Smith, D.C., and Wang, S. (2014). Small-molecule SMAC mimetics as new cancer therapeutics. Pharmacol. Ther. 144, 82-95.
4. Balakrishnan, M., Yant, S.R., Tsai, L., O'Sullivan, C., Bam, R.A., Tsai, A., Niedziela-Majka, A., Stray, K.M., Sakowicz, R., and Cihlar, T. (2013). Non-catalytic site HIV-1 integrase inhibitors disrupt core maturation and induce a reverse transcription block in target cells. PLoS ONE 8, e74163.
5. Basse, M.J., Betzi, S., Bourgeas, R., Bouzidi, S., Chetrit, B., Hamon, V., Morelli, X., and Roche, P. (2013). 2P2Idb: a structural database dedicated to orthosteric modulation of protein-protein interactions. Nucleic Acids Res. 41 (Database issue), D824-D827.
6. Benetatos, C.A., Mitsuuchi, Y., Burns, J.M., Neiman, E.M., Condon, S.M., Yu, G., Seipel, M.E., Kapoor, G.S., Laporte, M.G., Rippin, S.R., et al. (2014). Birinapant (TL32711), a bivalent SMAC mimetic, targets TRAF2-associated cIAPs, abrogates TNF-induced NF-κB activation, and is active in patient-derived xenograft models. Mol. Cancer Ther. 13, 867-879.
7. Bernal, F., Wade, M., Godes, M., Davis, T.N., Whitehead, D.G., Kung, A.L., Wahl, G.M., and Walensky, L.D. (2010). A stapled p53 helix overcomes HDMX-mediated suppression of p53. Cancer Cell 18, 411-422.
8. Boersma, M.D., Haase, H.S., Peterson-Kaufman, K.J., Lee, E.F., Clarke, O.B., Colman, P.M., Smith, B.J., Horne, W.S., Fairlie, W.D., and Gellman, S.H. (2012). Evaluation of diverse α/β-backbone patterns for functional α-helix mimicry: analogues of the Bim BH3 domain. J. Am. Chem. Soc. 134, 315-323.
9. Buckley, D.L., Gustafson, J.L., Van Molle, I., Roth, A.G., Tae, H.S., Gareiss, P.C., Jorgensen, W.L., Ciulli, A., and Crews, C.M. (2012a). Small-molecule inhibitors of the interaction between the E3 ligase VHL and HIF1α. Angew. Chem. Int. Ed. Engl. 51, 11463-11467.
10. Buckley, D.L., Van Molle, I., Gareiss, P.C., Tae, H.S., Michel, J., Noblin, D.J., Jorgensen, W.L., Ciulli, A., and Crews, C.M. (2012b). Targeting the von Hippel-Lindau E3 ubiquitin ligase using small molecules to disrupt the VHL/HIF-1α interaction. J. Am. Chem. Soc. 134, 4465-4468.
11. Buhrlage, S.J., Bates, C.A., Rowe, S.P., Minter, A.R., Brennan, B.B., Majmudar, C.Y., Wemmer, D.E., Al-Hashimi, H., and Mapp, A.K. (2009). Amphipathic small molecules mimic the binding mode and function of endogenous transcription factors. ACS Chem. Biol. 4, 335-344.
12. Busschots, K., Lopez-Garcia, L.A., Lammi, C., Stroba, A., Zeuzem, S., Piiper, A., Alzari, P.M., Neimanis, S., Arencibia, J.M., Engel, M., et al. (2012). Sub-strate- selective inhibition of protein kinase PDK1 by small compounds that bind to the PIF-pocket allosteric docking site. Chem. Biol. 19, 1152-1163.
13. Cai, Q., Sun, H., Peng, Y., Lu, J., Nikolovska-Coleska, Z., McEachern, D., Liu, L., Qiu, S., Yang, C.Y., Miller, R., et al. (2011). A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. J. Med. Chem. 54, 2714-2726.
14. Cancer Discovery (2014). BCL-2 inhibitor yields high response in CLL and SLL. Cancer Discov. 4, OF5.
15. Chang, Y.S., Graves, B., Guerlavais, V., Tovar, C., Packman, K., To, K.H., Olson, K.A., Kesavan, K., Gangurde, P., Mukherjee, A., et al. (2013). Stapled α-helical peptide drug development: a potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy. Proc. Natl. Acad. Sci. USA 110, E3445-E3454.
16. Cherepanov, P., Ambrosio, A.L., Rahman, S., Ellenberger, T., and Engelman, A. (2005). Structural basis for the recognition between HIV-1 integrase and transcriptional coactivator p75. Proc. Natl. Acad. Sci. USA 102, 17308-17313.
17. Clackson, T., and Wells, J.A. (1995). A hot spot of binding energy in a hormone-receptor interface. Science 267, 383-386.
18. Condon, S.M., Mitsuuchi, Y., Deng, Y., LaPorte, M.G., Rippin, S.R., Haimowitz, T., Alexander, M.D., Kumar, P.T., Hendi, M.S., Lee, Y.H., et al. (2014). Birinapant, a smac-mimetic with improved tolerability for the treatment of solid tumors and hematological malignancies. J. Med. Chem. 57, 3666-3677.
19. De Luca, L., Ferro, S., Morreale, F., De Grazia, S., and Chimirri, A. (2011). Inhibitors of the interactions between HIV-1 IN and the cofactor LEDGF/p75. ChemMedChem 6, 1184-1191.
20. DeLano, W.L., Ultsch, M.H., de Vos, A.M., and Wells, J.A. (2000). Convergent solutions to binding at a protein-protein interface. Science 287, 1279-1283.
21. Ding, Q., Zhang, Z., Liu, J.J., Jiang, N., Zhang, J., Ross, T.M., Chu, X.J., Bartkovitz, D., Podlaski, F., Janson, C., et al. (2013). Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development. J. Med. Chem. 56, 5979-5983.
22. Dubrez, L., Berthelet, J., and Glorian, V. (2013). IAP proteins as targets for drug development in oncology. Onco. Targets Ther. 9, 1285-1304.
23. Dueber, E.C., Schoeffler, A.J., Lingel, A., Elliott, J.M., Fedorova, A.V., Giannetti, A.M., Zobel, K., Maurer, B., Varfolomeev, E., Wu, P., et al. (2011). Antagonists induce a conformational change in cIAP1 that promotes autoubiquitination. Science 334, 376-380.
24. Engel, M., Hindie, V., Lopez-Garcia, L.A., Stroba, A., Schaeffer, F., Adrian, I., Imig, J., Idrissova, L., Nastainczyk, W., Zeuzem, S., et al. (2006). Allosteric activation of the protein kinase PDK1 with low molecular weight compounds. EMBO J. 25, 5469-5480.
25. Engelman, A., Kessl, J.J., and Kvaratskhelia, M. (2013). Allosteric inhibition of HIV-1 integrase activity. Curr. Opin. Chem. Biol. 17, 339-345.
26. Erickson, R.I., Tarrant, J., Cain, G., Lewin-Koh, S.C., Dybdal, N., Wong, H., Blackwood, E., West, K., Steigerwalt, R., Mamounas, M., et al. (2013). Toxicity profile of small-molecule IAP antagonist GDC-0152 is linked to TNF-α pharmacology. Toxicol. Sci. 131, 247-258.
27. Erlanson, D.A., Wells, J.A., and Braisted, A.C. (2004). Tethering: fragment-based drug discovery. Annu. Rev. Biophys. Biomol. Struct. 33, 199-223.
28. Fader, L.D., Malenfant, E., Parisien, M., Carson, R., Bilodeau, F., Landry, S., Pesant, M., Brochu, C., Morin, S., Chabot, C., et al. (2014). Discovery of BI 224436, a Noncatalytic Site Integrase Inhibitor (NCINI) of HIV-1. ACS Med. Chem. Lett. 5, 422-427.
29. Fenwick, C., Amad, M., Bailey, M.D., Bethell, R., Bös, M., Bonneau, P., Cordingley, M., Coulombe, R., Duan, J., Edwards, P., et al. (2014). Preclinical Profile of BI 224436, a Novel HIV-1 Non-Catalytic-Site Integrase Inhibitor. Antimicrob. Agents Chemother. 58, 3233-3244.
30. Filippakopoulos, P., and Knapp, S. (2014). Targeting bromodomains: epigenetic readers of lysine acetylation. Nat. Rev. Drug Discov. 13, 337-356.
31. Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W.B., Fedorov, O., Morse, E.M., Keates, T., Hickman, T.T., Felletar, I., et al. (2010). Selective inhibition of BET bromodomains. Nature 468, 1067-1073.
32. Flygare, J.A., Beresini, M., Budha, N., Chan, H., Chan, I.T., Cheeti, S., Cohen, F., Deshayes, K., Doerner, K., Eckhardt, S.G., et al. (2012). Discovery of a potent small-molecule antagonist of inhibitor of apoptosis (IAP) proteins and clinical candidate for the treatment of cancer (GDC-0152). J. Med. Chem. 55, 4101-4113.
33. Ford, M.L., and Larsen, C.P. (2009). Translating costimulation blockade to the clinic: lessons learned from three pathways. Immunol. Rev. 229, 294-306.
34. Fry, D.C. (2012). Small-molecule inhibitors of protein-protein interactions: how to mimic a protein partner. Curr. Pharm. Des. 18, 4679-4684.
35. Fulda, S., and Vucic, D. (2012). Targeting IAP proteins for therapeutic intervention in cancer. Nat. Rev. Drug Discov. 11, 109-124.
36. Fuller, J.C., Burgoyne, N.J., and Jackson, R.M. (2009). Predicting druggable binding sites at the protein-protein interface. Drug Discov. Today 14, 155-161.
37. Gadek, T.R., Burdick, D.J., McDowell, R.S., Stanley, M.S., Marsters, J.C., Jr., Paris, K.J., Oare, D.A., Reynolds, M.E., Ladner, C., Zioncheck, K.A., et al. (2002). Generation of an LFA-1 antagonist by the transfer of the ICAM-1 immunoregulatory epitope to a small molecule. Science 295, 1086-1089.
38. Gavenonis, J., Sheneman, B.A., Siegert, T.R., Eshelman, M.R., and Kritzer, J.A. (2014). Comprehensive analysis of loops at protein-protein interfaces for macrocycle design. Nat. Chem. Biol. 10, 716-722.
39. Gehling, V.S., Hewitt, M.C., Vaswani, R.G., Leblanc, Y., Côté, A., Nasveschuk, C.G., Taylor, A.M., Harmange, J.C., Audia, J.E., Pardo, E., et al. (2013). Discovery, Design, and Optimization of Isoxazole Azepine BET Inhibitors. ACS Med. Chem. Lett. 4, 835-840.
40. Gold, M.G., Barford, D., and Komander, D. (2006). Lining the pockets of kinases and phosphatases. Curr. Opin. Struct. Biol. 16, 693-701.
41. Guckian, K.M., and Scott, D.M. (2013). Inhibition of LFA-1/ICAM interaction for the treatment of autoimmune diseases. In Protein-Protein Interactions in Drug Discovery, A. Domling, ed. (Weinheim: Wiley-VCH Verlag).
42. Guo, W., Wisniewski, J.A., and Ji, H. (2014). Hot spot-based design of small-molecule inhibitors for protein-protein interactions. Bioorg. Med. Chem. Lett. 24, 2546-2554.
43. Hajduk, P.J., and Greer, J. (2007). A decade of fragment-based drug design: strategic advances and lessons learned. Nat. Rev. Drug Discov. 6, 211-219.
44. Hann, M.M., Leach, A.R., and Harper, G. (2001). Molecular complexity and its impact on the probability of finding leads for drug discovery. J. Chem. Inf. Comput. Sci. 41, 856-864.
45. Hartman, G.D., Egbertson, M.S., Halczenko, W., Laswell, W.L., Duggan, M.E., Smith, R.L., Naylor, A.M., Manno, P.D., Lynch, R.J., Zhang, G., et al. (1992). Non-peptide fibrinogen receptor antagonists. 1. Discovery and design of exosite inhibitors. J. Med. Chem. 35, 4640-4642.
46. He, M.M., Smith, A.S., Oslob, J.D., Flanagan, W.M., Braisted, A.C., Whitty, A., Cancilla, M.T., Wang, J., Lugovskoy, A.A., Yoburn, J.C., et al. (2005). Smallmolecule inhibition of TNF-alpha. Science 310, 1022-1025.
47. He, S., Senter, T.J., Pollock, J., Han, C., Upadhyay, S.K., Purohit, T., Gogliotti, R.D., Lindsley, C.W., Cierpicki, T., Stauffer, S.R., and Grembecka, J. (2014). High-affinity small-molecule inhibitors of the menin-mixed lineage leukemia (MLL) interaction closely mimic a natural protein-protein interaction. J. Med. Chem. 57, 1543-1556.
48. Higueruelo, A.P., Schreyer, A., Bickerton, G.R., Pitt, W.R., Groom, C.R., and Blundell, T.L. (2009). Atomic interactions and profile of small molecules disrupting protein-protein interfaces: the TIMBAL database. Chem. Biol. Drug Des. 74, 457-467.
49. Hopkins, A.L., Keserü, G.M., Leeson, P.D., Rees, D.C., and Reynolds, C.H. (2014). The role of ligand efficiency metrics in drug discovery. Nat. Rev. Drug Discov. 13, 105-121.
50. Huang, Y., Rich, R.L., Myszka, D.G., and Wu, H. (2003). Requirement of both the second and third BIR domains for the relief of X-linked inhibitor of apoptosis protein (XIAP)-mediated caspase inhibition by Smac. J. Biol. Chem. 278, 49517-49522.
51. Hwang, H., Vreven, T., Janin, J., and Weng, Z. (2010). Protein-protein docking benchmark version 4.0. Proteins 78, 3111-3114.
52. Infante, J.R., Dees, E.C., Olszanski, A.J., Dhuria, S.V., Sen, S., Cameron, S., and Cohen, R.B. (2014). Phase I dose-escalation study of LCL161, an oral inhibitor of apoptosis proteins inhibitor, in patients with advanced solid tumors. J. Clin. Oncol. Published online August 11, 2014. http://dx.doi.org/10.1200/JCO.2013.52.3993.
53. Johnson, D.K., and Karanicolas, J. (2013). Druggable protein interaction sites are more predisposed to surface pocket formation than the rest of the protein surface. PLoS Comput. Biol. 9, e1002951.
54. Keating, S.M., Clark, K.R., Stefanich, L.D., Arellano, F., Edwards, C.P., Bodary, S.C., Spencer, S.A., Gadek, T.R., Marsters, J.C., Jr., and Beresini, M.H. (2006). Competition between intercellular adhesion molecule-1 and a small-molecule antagonist for a common binding site on the alphal subunit of lymphocyte function-associated antigen-1. Protein Sci. 15, 290-303.
55. Khoo, K.H., Verma, C.S., and Lane, D.P. (2014). Drugging the p53 pathway: understanding the route to clinical efficacy. Nat. Rev. Drug Discov. 13, 217-236.
56. Koehler, M.F., Bergeron, P., Choo, E.F., Lau, K., Ndubaku, C., Dudley, D., Gibbons, P., Sleebs, B.E., Rye, C.S., Nikolakopoulos, G., et al. (2014). Structure-guided rescaffolding of selective antagonists of BCL-XL. ACS Med. Chem. Lett. 5, 662-667.
57. Kozakov, D., Hall, D.R., Chuang, G.Y., Cencic, R., Brenke, R., Grove, L.E., Beglov, D., Pelletier, J., Whitty, A., and Vajda, S. (2011). Structural conservation of druggable hot spots in protein-protein interfaces. Proc. Natl. Acad. Sci. USA 108, 13528-13533.
58. Kussie, P.H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A.J., and Pavletich, N.P. (1996). Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 274, 948-953.
59. Labbé, C.M., Laconde, G., Kuenemann, M.A., Villoutreix, B.O., and Sperandio, O. (2013). iPPI-DB: a manually curated and interactive database of small non-peptide inhibitors of protein-protein interactions. Drug Discov. Today 18, 958-968.
60. Lao, B.B., Grishagin, I., Mesallati, H., Brewer, T.F., Olenyuk, B.Z., and Arora, P.S. (2014). In vivo modulation of hypoxia-inducible signaling by topographical helix mimetics. Proc. Natl. Acad. Sci. USA 111, 7531-7536.
61. Lessard, J.A., and Crabtree, G.R. (2010). Chromatin regulatory mechanisms in pluripotency. Annu. Rev. Cell Dev. Biol. 26, 503-532.
62. Li, X., Srinivasan, S.R., Connarn, J., Ahmad, A., Young, Z.T., Kabza, A.M., Zuiderweg, E.R., Sun, D., and Gestwicki, J.E. (2013). Analogs of the Allosteric Heat Shock Protein 70 (Hsp70) Inhibitor, MKT-077, as Anti-Cancer Agents. ACS Med. Chem. Lett. 4. Published online September 17, 2013. http://dx.doi.org/10.1021/ml400204n.
63. Liu, Z., Sun, C., Olejniczak, E.T., Meadows, R.P., Betz, S.F., Oost, T., Herrmann, J., Wu, J.C., and Fesik, S.W. (2000). Structural basis for binding of Smac/DIABLO to the XIAP BIR3 domain. Nature 408, 1004-1008.
64. Livingston, D.J., Alexander, S., Bond, J., Briggs, T., Fraley, A., Hale, S., Landsman, T., Martinelli, R., Shortsleeves, K., and Terrett, N. (2012). Identification and characterization of synthetic small molecule macrocycle antagonists of human IL17A. http://www.ensemblediscovery.com/news/pdfs/ACR%20Poster%20DJL-v1-1%20(2).pdf.
65. London, N., Raveh, B., Movshovitz-Attias, D., and Schueler-Furman, O. (2010). Can self-inhibitory peptides be derived from the interfaces of globular protein-protein interactions? Proteins 78, 3140-3149.
66. London, N., Raveh, B., and Schueler-Furman, O. (2013). Druggable protein-protein interactions-from hot spots to hot segments. Curr. Opin. Chem. Biol. 17, 952-959.
67. Maurer, T., Garrenton, L.S., Oh, A., Pitts, K., Anderson, D.J., Skelton, N.J., Fauber, B.P., Pan, B., Malek, S., Stokoe, D., et al. (2012). Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity. Proc. Natl. Acad. Sci. USA 109, 5299-5304.
68. McLure, K.G., Gesner, E.M., Tsujikawa, L., Kharenko, O.A., Attwell, S., Campeau, E., Wasiak, S., Stein, A., White, A., Fontano, E., et al. (2013). RVX-208, an inducer of ApoA-I in humans, is a BET bromodomain antagonist. PLoS ONE 8, e83190.
69. Milroy, L.G., Grossmann, T.N., Hennig, S., Brunsveld, L., and Ottmann, C. (2014). Modulators of protein-protein interactions.Chem. Rev. 114, 4695-4748.
70. Mirguet, O., Gosmini, R., Toum, J., Clément, C.A., Barnathan, M., Brusq, J.M., Mordaunt, J.E., Grimes, R.M., Crowe, M., Pineau, O., et al. (2013). Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains. J. Med. Chem. 56, 7501-7515.
71. Miyazaki, M., Naito, H., Sugimoto, Y., Kawato, H., Okayama, T., Shimizu, H., Miyazaki, M., Kitagawa, M., Seki, T., Fukutake, S., et al. (2013). Lead optimization of novel p53-MDM2 interaction inhibitors possessing dihydroimidazothiazole scaffold. Bioorg. Med. Chem. Lett. 23, 728-732.
72. Ndubaku, C., Varfolomeev, E., Wang, L., Zobel, K., Lau, K., Elliott, L.O., Maurer, B., Fedorova, A.V., Dynek, J.N., Koehler, M., et al. (2009). Antagonism of c-IAP and XIAP proteins is required for efficient induction of cell death by small-molecule IAP antagonists. ACS Chem. Biol. 4, 557-566.
73. Nussinov, R., and Tsai, C.J. (2014). Unraveling structural mechanisms of allosteric drug action. Trends Pharmacol. Sci. 35, 256-264.
74. Oltersdorf, T., Elmore, S.W., Shoemaker, A.R., Armstrong, R.C., Augeri, D.J., Belli, B.A., Bruncko, M., Deckwerth, T.L., Dinges, J., Hajduk, P.J., et al. (2005). An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435, 677-681.
75. Oost, T.K., Sun, C., Armstrong, R.C., Al-Assaad, A.S., Betz, S.F., Deckwerth, T.L., Ding, H., Elmore, S.W., Meadows, R.P., Olejniczak, E.T., et al. (2004). Discovery of potent antagonists of the antiapoptotic protein XIAP for the treatment of cancer. J. Med. Chem. 47, 4417-4426.
76. Ostrem, J.M., Peters, U., Sos, M.L., Wells, J.A., and Shokat, K.M. (2013). K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 503, 548-551.
77. Perkins, J.R., Diboun, I., Dessailly, B.H., Lees, J.G., and Orengo, C. (2010). Transient protein-protein interactions: structural, functional, and network properties. Structure 18, 1233-1243.
78. Petsalaki, E., and Russell, R.B. (2008). Peptide-mediated interactions in biological systems: new discoveries and applications. Curr. Opin. Biotechnol. 19, 344-350.
79. Raj, M., Bullock, B.N., and Arora, P.S. (2013). Plucking the high hanging fruit: a systematic approach for targeting protein-protein interactions. Bioorg. Med. Chem. 21, 4051-4057.
80. Ray-Coquard, I., Blay, J.Y., Italiano, A., Le Cesne, A., Penel, N., Zhi, J., Heil, F., Rueger, R., Graves, B., Ding, M., et al. (2012). Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study. Lancet Oncol. 13, 1133-1140.
81. Roberts, A.W., Seymour, J.F., Brown, J.R., Wierda, W.G., Kipps, T.J., Khaw, S.L., Carney, D.A., He, S.Z., Huang, D.C., Xiong, H., et al. (2012). Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J. Clin. Oncol. 30, 488-496.
82. Rohn, J. (2012). Tensha therapeutics. Nat. Biotechnol. 30, 305.
83. Rudin, C.M., Hann, C.L., Garon, E.B., Ribeiro de Oliveira, M., Bonomi, P.D., Camidge, D.R., Chu, Q., Giaccone, G., Khaira, D., Ramalingam, S.S., et al. (2012). Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin. Cancer Res. 18, 3163-3169.
84. Sadowsky, J.D., Burlingame, M.A., Wolan, D.W., McClendon, C.L., Jacobson, M.P., and Wells, J.A. (2011). Turning a protein kinase on or off from a single allosteric site via disulfide trapping. Proc. Natl. Acad. Sci. USA 108, 6056-6061.
85. Sattler, M., Liang, H., Nettesheim, D., Meadows, R.P., Harlan, J.E., Eberstadt, M., Yoon, H.S., Shuker, S.B., Chang, B.S., Minn, A.J., et al. (1997). Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis. Science 275, 983-986.
86. Schaumberg, D.A., Sullivan, D.A., Buring, J.E., and Dana, M.R. (2003). Prevalence of dry eye syndrome among US women. Am. J. Ophthalmol. 136, 318-326.
87. Schwab, N., Ulzheimer, J.C., Fox, R.J., Schneider-Hohendorf, T., Kieseier, B.C., Monoranu, C.M., Staugaitis, S.M., Welch, W., Jilek, S., Du Pasquier, R.A., et al. (2012). Fatal PML associated with efalizumab therapy: insights into integrin aLb2 in JC virus control. Neurology 78, 458-467, discussion 465.
88. Sharma, A., Slaughter, A., Jena, N., Feng, L., Kessl, J.J., Fadel, H.J., Malani, N., Male, F., Wu, L., Poeschla, E., et al. (2014). A new class of multimerization selective inhibitors of HIV-1 integrase. PLoS Pathog. 10, e1004171.
89. Shi, A., Murai, M.J., He, S., Lund, G., Hartley, T., Purohit, T., Reddy, G., Chruszcz, M., Grembecka, J., and Cierpicki, T. (2012). Structural insights into inhibition of the bivalent menin-MLL interaction by small molecules in leukemia. Blood 120, 4461-4469.
90. Shima, F., Yoshikawa, Y., Ye, M., Araki, M., Matsumoto, S., Liao, J., Hu, L., Sugimoto, T., Ijiri, Y., Takeda, A., et al. (2013). In silico discovery of small-molecule Ras inhibitors that display antitumor activity by blocking the Ras-effector interaction. Proc. Natl. Acad. Sci. USA 110, 8182-8187.
91. Shimaoka, M., Salas, A., Yang, W., Weitz-Schmidt, G., and Springer, T.A. (2003). Small molecule integrin antagonists that bind to the beta2 subunit I-like domain and activate signals in one direction and block them in the other. Immunity 19, 391-402.
92. Shire (2014). Shire plans to submit a new drug application to FDA for lifitegrast for dry eye disease in adults. http://www.shire.com/shireplc/en/investors/investorsnews/irshirenews?id=951.
93. Silvian, L.F., Friedman, J.E., Strauch, K., Cachero, T.G., Day, E.S., Qian, F., Cunningham, B., Fung, A., Sun, L., Shipps, G.W., et al. (2011). Small molecule inhibition of the TNF family cytokine CD40 ligand through a subunit fracture mechanism. ACS Chem. Biol. 6, 636-647.
94. Smith, M.C., and Gestwicki, J.E. (2012). Features of protein-protein interactions that translate into potent inhibitors: topology, surface area and affinity. Expert Rev. Mol. Med. 14, e16.
95. Souers, A.J., Leverson, J.D., Boghaert, E.R., Ackler, S.L., Catron, N.D., Chen, J., Dayton, B.D., Ding, H., Enschede, S.H., Fairbrother, W.J., et al. (2013). ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat. Med. 19, 202-208.
96. Stockman, B.J., Kothe, M., Kohls, D., Weibley, L., Connolly, B.J., Sheils, A.L., Cao, Q., Cheng, A.C., Yang, L., Kamath, A.V., et al. (2009). Identification of allosteric PIF-pocket ligands for PDK1 using NMR-based fragment screening and 1H-15N TROSY experiments. Chem. Biol. Drug Des. 73, 179-188.
97. Sun, Q., Burke, J.P., Phan, J., Burns, M.C., Olejniczak, E.T., Waterson, A.G., Lee, T., Rossanese, O.W., and Fesik, S.W. (2012). Discovery of small molecules that bind to K-Ras and inhibit Sos-mediated activation. Angew. Chem. Int. Ed. Engl. 51, 6140-6143.
98. Sun, H., Lu, J., Liu, L., Yang, C.Y., and Wang, S. (2014). Potent and selective small-molecule inhibitors of cIAP1/2 proteins reveal that the binding of Smac mimetics to XIAP BIR3 is not required for their effective induction of cell death in tumor cells. ACS Chem. Biol. 9, 994-1002.
99. Tovar, C., Graves, B., Packman, K., Filipovic, Z., Higgins, B., Xia, M., Tardell, C., Garrido, R., Lee, E., Kolinsky, K., et al. (2013). MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models. Cancer Res. 73, 2587-2597.
100. Tse, C., Shoemaker, A.R., Adickes, J., Anderson, M.G., Chen, J., Jin, S., Johnson, E.F., Marsh, K.C., Mitten, M.J., Nimmer, P., et al. (2008). ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 68, 3421-3428.
101. Vassilev, L.T., Vu, B.T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004). In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303, 844-848.
102. Venkatesan, K., Rual, J.F., Vazquez, A., Stelzl, U., Lemmens, I., Hirozane-Kishikawa, T., Hao, T., Zenkner, M., Xin, X., Goh, K.I., et al. (2009). An empirical framework for binary interactome mapping. Nat. Methods 6, 83-90.
103. Vidler, L.R., Brown, N., Knapp, S., and Hoelder, S. (2012). Druggability analysis and structural classification of bromodomain acetyl-lysine binding sites. J. Med. Chem. 55, 7346-7359.
104. Vollmuth, F., Blankenfeldt, W., and Geyer, M. (2009). Structures of the dual bromodomains of the P-TEFb-activating protein Brd4 at atomic resolution. J. Biol. Chem. 284, 36547-36556.
105. Wang, Y., Coulombe, R., Cameron, D.R., Thauvette, L., Massariol, M.J., Amon, L.M., Fink, D., Titolo, S., Welchner, E., Yoakim, C., et al. (2004). Crystal structure of the E2 transactivation domain of human papillomavirus type 11 bound to a protein interaction inhibitor. J. Biol. Chem. 279, 6976-6985.
106. Wang, A.M., Miyata, Y., Klinedinst, S., Peng, H.M., Chua, J.P., Komiyama, T., Li, X., Morishima, Y., Merry, D.E., Pratt, W.B., et al. (2013a). Activation of Hsp70 reduces neurotoxicity by promoting polyglutamine protein degradation. Nat. Chem. Biol. 9, 112-118.
107. Wang, N., Majmudar, C.Y., Pomerantz, W.C., Gagnon, J.K., Sadowsky, J.D., Meagher, J.L., Johnson, T.K., Stuckey, J.A., Brooks, C.L., 3rd, Wells, J.A., and Mapp, A.K. (2013b). Ordering a dynamic protein via a small-molecule stabilizer. J. Am. Chem. Soc. 135, 3363-3366.
108. Wei, S.J., Joseph, T., Sim, A.Y., Yurlova, L., Zolghadr, K., Lane, D., Verma, C., and Ghadessy, F. (2013). In vitro selection of mutant HDM2 resistant to Nutlin inhibition. PLoS ONE 8, e62564.
109. Wells, J.A., and McClendon, C.L. (2007). Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature 450, 1001-1009.
110. Wilson, C.G., and Arkin, M.R. (2011). Small-molecule inhibitors of IL-2/IL-2R: lessons learned and applied. Curr. Top. Microbiol. Immunol. 348, 25-59.
111. Winter, A., Higueruelo, A.P., Marsh, M., Sigurdardottir, A., Pitt, W.R., and Blundell, T.L. (2012). Biophysical and computational fragment-based approaches to targeting protein-protein interactions: applications in structure-guided drug discovery. Q. Rev. Biophys. 45, 383-426.
112. Wong, H., Gould, S.E., Budha, N., Darbonne, W.C., Kadel, E.E., 3rd, La, H., Alicke, B., Halladay, J.S., Erickson, R., Portera, C., et al. (2013). Learning and confirming with preclinical studies: modeling and simulation in the discovery of GDC-0917, an inhibitor of apoptosis proteins antagonist. Drug Metab. Dispos. 41, 2104-2113.
113. Yang, C., and Novack, D.V. (2013). Anti-cancer IAP antagonists promote bone metastasis: a cautionary tale. J. Bone Miner. Metab. 31, 496-506.
114. Zhang, Z., Ding, Q., Liu, J.J., Zhang, J., Jiang, N., Chu, X.J., Bartkovitz, D., Luk, K.C., Janson, C., Tovar, C., et al. (2014). Discovery of potent and selective spiroindolinone MDM2 inhibitor, RO8994, for cancer therapy. Bioorg. Med. Chem. 22, 4001-4009.
115. Zhao, Y., Yu, S., Sun, W., Liu, L., Lu, J., McEachern, D., Shargary, S., Bernard, D., Li, X., Zhao, T., et al. (2013). A potent small-molecule inhibitor of the MDM2-p53 interaction (MI-888) achieved complete and durable tumor regression in mice. J. Med. Chem. 56, 5553-5561.
116. Zhong, M., Gadek, T.R., Bui, M., Shen, W., Burnier, J., Barr, K.J., Hanan, E.J., Oslob, J.D., Yu, C.H., Zhu, J., et al. (2012). Discovery and development of potent LFA-1/ICAM-1 antagonist SAR 1118 as an ophthalmic solution for treating dry eye. ACS Med. Chem. Lett. 3, 203-206.